Park Jae-Don – Chairman, Korea Pharma
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Korea Pharma Co. Ltd (KP) has sought to help people keep and improve their health for more than 30 years, based on the principles of “respect for human life and dignity.” With fully validated cGMP facility and a strong quality control system, KP’s products are safe, stable, and of high quality and efficacy. At present, KP is seeking to achieve a healthier future for the 21st century by concentrating on the constant research and development of various kinds of pharmaceutical products.
KP also manufactures products for multinational companies such as Mundi Pharma and Stiefel, developing high quality preparations using advanced Drug Delivery Systems. In all, KP exports more than 40 kinds of products to over 16 countries.
Contact Details
87 Jeyakgongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do
Korea (135-060)
Tel; +82-2-558-1277
webmaster@koreapharma.co.kr
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Could you please introduce KPMA and explain the role it plays within the South Korean pharmaceutical industry? KPMA is the only association in South Korea regrouping the whole range of…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
See our Cookie Privacy Policy Here
